Formulation of rifampicin-cyclodextrin complexes for lung nebulization

Journal of Controlled Release

Volumn 129, Issue 2, 2008, Pages 93-99

  Tewes, Frédéric ^a,b   Brillault, Julien ^a,b   Couet, William ^a,b   Olivier, Jean Christophe ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE POITIERS   (France)

Author keywords

Calu 3; Cyclodextrin; Lung; Permeability; Rifampicin

Indexed keywords

BIOLOGICAL ORGANS; CADMIUM; CADMIUM COMPOUNDS; CHEMOTHERAPY; CRACK DETECTION; CYCLODEXTRINS; DATA STORAGE EQUIPMENT; DRUG DELIVERY; DRUG DOSAGE; DRUG THERAPY; GRAPHIC METHODS; HEALTH; METEOROLOGICAL INSTRUMENTS; PHOTOACOUSTIC EFFECT; SILANES; SOLUBILITY; TERNARY SYSTEMS;

ACINETOBACTER; ANTIBACTERIAL ACTIVITIES; CASCADE IMPACTOR; CD(II) COMPLEXES; CYCLODEXTRIN (CYDS); CYCLODEXTRINS (CDS); DRUG CONCENTRATIONS; IN-VITRO; PH-DEPENDENT; PHASE SOLUBILITY; PULMONARY INFECTIONS; RIFAMPICIN (RF); SIDE EFFECTS; SOLUBILITY ENHANCEMENTS; TREATMENT EFFICIENCY;

SULFUR COMPOUNDS;

BETA CYCLODEXTRIN; CYCLODEXTRIN; DRUG CARRIER; RIFAMPICIN;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ARTICLE; CELL STRAIN; CONTROLLED STUDY; DILUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG; MINIMUM INHIBITORY CONCENTRATION; NEBULIZATION; PARTICLE SIZE; PRIORITY JOURNAL;

ACINETOBACTER BAUMANNII; ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; BETA-CYCLODEXTRINS; CELL LINE; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; MODELS, CHEMICAL; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PERMEABILITY; RESPIRATORY MUCOSA; RIFAMPIN; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 45049083552     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.04.007     Document Type: Article

References (32)

1. Montero A., Corbella X., and Ariza J. Clinical relevance of Acinetobacter baumannii ventilator-associated pneumonia. Critical Care Medicine 31 10 (2003) 2557-2559
2. Da Silva G., Dijkshoorn L., van der Reijden T., van Strijen B., and Duarte A. Identification of widespread, closely related Acinetobacter baumannii isolates in Portugal as a subgroup of European clone II. Clinical Microbiology and Infection 13 2 (2007) 190-195
3. Kuo L.C., Lai C.C., Liao C.H., Hsu C.K., Chang Y.L., Chang C.Y., and Hsueh P.R. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features antimicrobial therapy and outcome. Clinical Microbiology and Infection 13 2 (2007) 196-198
4. Saballs M., Pujol M., Tubau F., Pena C., Montero A., Dominguez M.A., Gudiol F., and Ariza J. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. Journal of Antimicrobial Chemotherapy 58 3 (2006) 697-700
5. Wroblewska M.M., Towner K.J., Marchel H., and Luczak M. Emergence and spread of carbapenem-resistant strains of Acinetobacter baumannii in a tertiary-care hospital in Poland. Clinical Microbiology and Infection 13 5 (2007) 490-496
6. Bogaerts P., Naas T., Wybo I., Bauraing C., Soetens O., Pie?rard D., Nordmann P., and Glupczynski Y. Outbreak of infection by carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-58 in Belgium. Journal of Clinical Microbiology 44 11 (2006) 4189-4192
7. Coelho J.M., Turton J.F., Kaufmann M.E., Glover J., Woodford N., Warner M., Palepou M.F., Pike R., Pitt T.L., Patel B.C., and Livermore D.M. Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England. Journal of Clinical Microbiology 44 10 (2006) 3623-3627
8. Bertini A., Giordano A., Varesi P., Villa L., Mancini C., and Carattoli A. First report of the carbapenem-hydrolyzing oxacillinase OXA-58 in Acinetobacter baumannii isolates in Italy. Antimicrobial Agents and Chemotherapy 50 6 (2006) 2268-2269
9. Trottier V., Namias N., Pust D.G., Nuwayhid Z., Manning R., Marttos Jr. A.C., Dunham M.B., Schulman C.I., and McKenney M.G. Outcomes of Acinetobacter baumannii infection in critically ill surgical patients. Surgical Infections 8 4 (2007) 437-443
10. Holloway K.P., Rouphael N.G., Wells J.B., King M.D., and Blumberg H.M. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumanii infections in the intensive care unit. Annals of Pharmacotherapy 40 11 (2006) 1939-1945
11. Kallel H., Bahloul M., Hergafi L., Akrout M., Ketata W., Chelly H., Hamida C.B., Rekik N., Hammami A., and Bouaziz M. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. International Journal of Antimicrobial Agents 28 4 (2006) 366-369
12. Li J., Rayner C.R., Nation R.L., Owen R.J., Spelman D., Tan K.E., and Liolios L. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 50 9 (2006) 2946-2950
13. Rodriguez-Hernandez M.J., Saugar J., Docobo-Perez F., de la Torre B.G., Pachon-Ibanez M.E., Garcia-Curiel A., Fernandez-Cuenca F., Andreu D., Rivas L., and Pachon J. Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy 58 1 (2006) 95-100
14. Gumbo T., Louie A., Deziel M.R., Liu W., Parsons L.M., Salfinger M., and Drusano G.L. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrobial Agents and Chemotherapy 51 11 (2007) 3781-3788
15. Henwood S.Q., Liebenberg W., Tiedt L.R., Lötter A.P., and de Villiers M.M. Characterization of the solubility and dissolution properties of several new rifampicin polymorphs, solvates, and hydrates. Drug Development and Industrial Pharmacy 27 10 (2001) 1017-1030
16. Agrawal S., and Panchagnula R. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations. International Journal of Pharmaceutics 287 1-2 (2004) 97-112
17. Louey M.D., and Garcia-Contreras L. Controlled release products for respiratory delivery. American Pharmaceutical Review 7 4 (2004) 82-87
18. Evrard B., Bertholet P., Gueders M., Flament M.P., Piel G., Delattre L., Gayot A., Leterme P., Foidart J.M., and Cataldo D. Cyclodextrins as a potential carrier in drug nebulization. Journal of Controlled Release 96 3 (2004) 403-410
19. Forbes B., and Ehrhardt C. Human respiratory epithelial cell culture for drug delivery applications. European Journal of Pharmaceutics and Biopharmaceutics 60 2 (2005) 193-205
20. Loftsson T., Hreinsdottir D., and Masson M. Evaluation of cyclodextrin solubilization of drugs. International Journal of Pharmaceutics 302 1-2 (2005) 18-28
21. Lundquist S., Renftel M., Brillault J., Fenart L., Cecchelli R., and Dehouck M.P. Prediction of drug transport through the blood-brain barrier in vivo: a comparison between two in vitro cell models. Pharmaceutical Research 19 7 (2002) 976-981
22. Majoral C., Pape A.L., Diot P., and Vecellio L. Comparison of various methods for processing cascade impactor data. Aerosol Science and Technology 40 9 (2006) 672-682
23. The Merck Index. 11th edn. Monograph vol. 8215 (1989) 1308
24. Rao B.P., Suresh S., Narendra C., and Balasangameshwer. Physicochemical characterization of β-cyclodextrin and hydroxy ethyl β-cyclodextrin complexes of rifampicin. Ars Pharmaceutica 47 1 (2006) 37-59
25. Brewster M.E., and Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Advanced Drug Delivery Reviews 59 7 (2007) 645-666
26. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Advanced Drug Delivery Reviews 58 9-10 (2006) 1030-1060
27. Tsamaloukas A., Szadkowska H., Slotte P.J., and Heerklotz H. Interactions of cholesterol with lipid membranes and cyclodextrin characterized by calorimetry. Biophysical Journal 89 2 (2005) 1109-1119
28. Matilainen L., Toropainen T., Vihola H., Hirvonen J., Jarvinen T., Jarho P., and Jarvinen K. In vitro toxicity and permeation of cyclodextrins in Calu-3 cells. Journal of Controlled Release 126 1 (2008) 10-16
29. Mariappan T.T., and Singh S. Evidence of efflux-mediated and saturable absorption of rifampicin in rat intestine using the ligated loop and everted gut sac techniques. Molecular Pharmaceutics 1 5 (2004) 363-367
30. Mariappan T.T., and Singh S. Positioning of rifampicin in the Biopharmaceutics Classification System (BCS). Clinical Research and Regulatory Affairs 23 1 (2006) 1-10
31. Chan E.C.Y., Tan W.L., Ho P.C., and Fang L.J. Modeling Caco-2 permeability of drugs using immobilized artificial membrane chromatography and physicochemical descriptors. Journal of Chromatography A 1072 2 (2005) 159-168
32. Garcia-Contreras L., Cooney D.J., Smyth H.D.C., Zimmerer R.O., Pipkin J.D., and Hickey A.J. Evaluation of cyclodextrin-rifampicin solutions in Calu-3 monolayer cell culture system. In: Dalby R.N., Byron P.R., Peart J., Suman J.D., and Farr S.J. (Eds). Respiratory Drug Delivery IX vol. III (2004), Davis Healthcare International, River Grove 797-800